Work

Generation of an anti-CD5 CAR knock-in human induced pluripotent stem cell line using CRISPR/Cas9 technology

Year: 2025

Type: article

Abstract: Theanti-CD5 chimeric antigen receptor (CAR)isa genetically engineered immune cell therapydevelopedto targetCD5-associatedhematologic malignancies,such asT-cell lymphoma and leukemia.UsingCRISPR/Cas9-mediated gene targeting, wegeneratedananti-CD5 CAR knock-in human induced pluripotent stem cell (iPSC) linethat stably expresses the CAR constructand is detectable via FLAG tag and GFP markers. Thisengineeredcell linemaintainsstem cell morphology,displaysa normal karyotype, andexhibits robustexpression ofpluripotency markers while retaining differentiation potential.

Source: Stem Cell Research

DOI: 10.1016/j.scr.2025.103731

Authors: Shuoting Wang, Xinrui Guo, Han Yan, Tiancheng Zhou, Jiajun Liu

Institutions: Sun Yat-sen University, Third Affiliated Hospital of Sun Yat-sen University, Chinese Academy of Sciences, Guangzhou Institutes of Biomedicine and Health

Language: English

Topic: Pluripotent Stem Cells Research

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,360